Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.22 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in syncytiotrophoblasts | 0.75 |
| chemistry Open Targets | compounds already reach it: piromelatine, agomelatine, ramelteon +2 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 3 stopped | 0.40 |
| literature PubMed | 3 Parkinson's papers of 451 | 0.82 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1918
Sealed predictions
- MTNR1B in dopamine neurons, braak-0.65 (p 0.058) → -0.06 (p 0.873)receipt 1926
Swarm cases
receipt 1926: MTNR1B in dopamine neurons, braak
- power
- full sample -0.33 (p 0.179, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.328, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.170, n 18). could be the mix.
- skeptic
- leave-one-out range -0.50 to -0.25, sign flips 0; without severely affected donors -0.33 (p 0.179, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MTNR1B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts